Analysis of first-line treatment (tx) patterns in advanced non-small cell lung cancer (NSCLC) patients (pts) with compromised performance status (PS), organ dysfunction (dfxn) or other significant comorbidities.
Julia Judd(Palmetto Hematology Oncology), Martin J. Edelman(Fox Chase Cancer Center), Elizabeth A. Handorf(Fox Chase Cancer Center), Brinda Gupta(Georgetown University)
Cited by 0
Related Papers
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Prospective Assessment of Pediatrician-Diagnosed Food Protein–Induced Allergic Proctocolitis by Gross or Occult Blood
|The Journal of Allergy and Clinical Immunology In Practice|2020|101
Improving the Radiosensitivity of Radioresistant and Hypoxic Glioblastoma
|Future Oncology|2010|60